Global Expansion of Cancer Treatment Technology
On 10 June 2026, Cosylab and Heron Neutron Medical Corp. announced the signing of a Letter of Intent. This agreement establishes a strategic framework for the global deployment of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) systems.
The collaboration aims to develop and integrate sophisticated software solutions for AB-BNCT. Cosylab’s mission-critical software expertise and Heron’s comprehensive BNCT platforms will enhance international market access and business development.
“AB-BNCT is emerging as one of the most promising approaches for treating difficult-to-treat and recurrent cancers,” stated Mark Pleško, CEO of Cosylab. This partnership reinforces their strategic focus on advancing radiation therapy technologies and expanding their reach in the Asia-Pacific region and beyond.
Strengthening Global Cancer Treatment
The joint effort between Cosylab and Heron Neutron Medical Corp. aims to drive broader clinical adoption of AB-BNCT. This advanced cancer treatment targets complex and recurrent cases, offering new hope for patients worldwide.
According to Shen Hsiao-Lien, General Manager of Heron Neutron Medical Corp., the agreement is a crucial step in Heron’s international growth strategy. The collaboration with Cosylab will strengthen cross-regional capabilities and support the rapid scaling of AB-BNCT solutions in global markets.
Founded in 2001, Cosylab is headquartered in Ljubljana, Slovenia. The company develops software and control systems for the world’s most demanding scientific and medical technology environments, including particle accelerators and radiation therapy systems. Cosylab has a global presence across research institutions, hospitals, and industrial facilities.
Heron Neutron Medical Corp. develops integrated AB-BNCT systems, including accelerator technologies, neutron beamlines, treatment platforms, and full clinical workflow integration. The company is dedicated to advancing innovative cancer treatment solutions and expanding global access to BNCT.
In 2025, the global cancer treatment market was valued at approximately $158 billion, reflecting a growing demand for advanced therapies like AB-BNCT. Cosylab and Heron’s collaboration could potentially tap into this expanding market, driving innovation and accessibility.
